Despite the use of modern immunochemotherapy regimens, almost 50% of patients with diffuse large-B-cell lymphoma will relapse. Current prognostic models, including the International Prognostic Index, incorporate patient and tumor characteristics. In contrast, recent observations show that variables related to host adaptive immunity and the tumor microenvironment are significant prognostic variables in non-Hodgkin lymphoma. Therefore, we retrospectively examined the absolute monocyte and lymphocyte counts as prognostic variables in a cohort of 366 diffuse large-B-cell lymphoma patients who were treated between 1993 and 2007 and followed at a single institution. The absolute monocyte and lymphocyte counts in univariate analysis predicted progression-free and overall survival when analyzed as continuous and dichotomized variables. On multivariate analysis performed with factors included in the IPI, the absolute monocyte and lymphocyte counts remained independent predictors of progression-free and overall survival. Therefore, the absolute monocyte and lymphocyte counts were combined to generate a prognostic score that identified patients with an especially poor overall survival. This prognostic score was independent of the IPI and added to its ability to identify high-risk patients.
Introduction
The International Prognostic Index (IPI) is currently the standard prognostic tool used to predict clinical outcomes for patients with diffuse large-B-cell lymphoma (DLBCL). Developed in the pre-rituximab era, the IPI was able to stratify patients into four discrete groups with 5-year overall survival (OS) ranging from approximately 25 to 75%. However, with improved outcomes attributed to the addition of rituximab, the identification of a high-risk subset of patients with an anticipated 5-year survival of less than 50% remains a challenge with use of the IPI alone. 1, 2 Gene-expression profiling, [3] [4] [5] [6] [7] immunohistochemistry-based detection of prognostic biomarkers [8] [9] [10] [11] [12] [13] [14] [15] [16] and early interim analysis with positron emission tomography 17, 18 following the initiation of immunochemotherapy have all been explored as predictors that may identify high-risk patients. Although promising, many of these methods are costly, difficult to obtain, not easily interpreted and require further validation. Therefore, the identification of prognostic factors that are inexpensive, widely available and easily interpreted by clinicians engaged in the care of patients with DLBCL is needed.
Most of the proposed prognostic factors utilized in DLBCL include solely patient or tumor characteristics. However, geneexpression profiling studies in non-Hodgkin lymphomas (NHL) show that gene expression by tumor-infiltrating lymphocytes and myeloid-derived cells predict clinical outcomes. 3, 19 Lymphocytes have an important role in immune surveillance in NHL, a view supported by the observation that lymphopenia is an adverse prognostic factor in NHL of various subtypes, including DLBCL, [20] [21] [22] [23] and is widely considered an important surrogate marker of immunological reconstitution following stem cell transplantation in NHL. 24 Monocytes and lymphomaassociated macrophages (LAMs) contribute to the suppression of host anti-tumor immunity and the promotion of tumor angiogenesis. Furthermore, monocytes may also provide trophic factors that directly promote the growth and survival of malignant lymphocytes, as recently shown in both B-and T-cell-derived NHL. 25, 26 Therefore, the aim of this study was to devise a prognostic model that is comprised of immunologically relevant host factors that is simple, applicable for routine clinical use, and sufficient to identify high-risk patients. As myeloid cells, including monocytes and their progeny, promote lymphomagenesis both directly, via the provision of trophic factors, and indirectly via the suppression of host immunity and stimulation of tumor angiogenesis, we examined the peripheral blood monocyte count at diagnosis as a prognostic factor for survival in DLBCL patients.
Patients and methods

Patients
Consecutive patients with DLBCL who were evaluated and treated with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) or R-CHOP (rituximab-cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) at the Mayo Clinic, Rochester between 1993 and 2007 were considered for study participation. HIV-positive patients were excluded from this study. The laboratory values were obtained from routine automated complete blood count (CBC) determination at the time of diagnosis. 27 Patient data was collected and entered into the Mayo Clinic Lymphoma Database. Our study sample included 366 DLBCL patients, none of whom declined to participate in this retrospective review. An additional 26 patients were eligible for study participation, but were excluded owing to missing laboratory data. Study approval was granted by the Mayo Clinic Institutional Review Board, in accordance with US federal regulations and the Declaration of Helsinki.
Study objective
The primary objective of the study was to determine the prognostic significance of the absolute monocyte and lymphocyte counts at diagnosis with both OS and progression-free survival (PFS). The absolute monocyte count (AMC) and absolute lymphocyte count (ALC) were obtained from a standard CBC obtained at the time of diagnosis. The secondary study objective was to determine whether the AMC or ALC are independently significant prognostic factors when compared with the IPI. Patient and disease characteristics included in the IPI (age (X60 vs o60 years), Ann Arbor stage (III/IV vs I/II), Eastern Cooperative Oncology Group performance status (41 vs p1), lactate dehydrogenase (4normal vs normal for age/sex) and the number of extranodal sites of disease (41 vs p1)) were utilized. 28 
Statistical analysis
PFS and OS were estimated using the Kaplan-Meier method and two-tailed log-rank test. 29 Response criteria were based on the criteria from the International Harmonization Project. 30 PFS was calculated from the date of diagnosis to the date of disease progression or last follow-up. OS was calculated from the date of diagnosis to the date of death or last follow-up. The AMC was analyzed as both a continuous and dichotomized variable using a median split. Receiver operating characteristics analysis was also performed (Cox's regression analysis) to determine the optimal cut-point for both the AMC and ALC. However, the optimal AMC cut-point determined by receiver operating characteristics analysis for the AMC (610/ml) was nearly identical to the median AMC (data not shown). Therefore, a median split was selected for subsequent analyses using the AMC. The optimal cut-point for the ALC by receiver operating characteristic analysis was 1470/ml. However, as an ALC cutpoint of 1000/ml has been utilized in previous studies, 23, 31, 32 and failed to yield a significant difference in the ability to risk stratify patients by OS when compared with the cut-point selected by receiver operating characteristic analysis (data not shown), we chose to dichotomize the ALC using a cut-point of 1000/ml. The Cox proportional hazards model was used to evaluate the AMC and ALC as prognostic factors for PFS and OS and to adjust for other known prognostic variables included in the IPI. 33 P-values were not adjusted for multiple comparisons. All two-sided P-values o0.05 were determined to be statistically significant.
Results
Patient characteristics
The median age at diagnosis for this cohort of 366 DLBCL patients was 64 years (range, 20-92 years), as summarized in Table 1 . Of these, 58% of patients were men. Median follow-up following diagnosis was 50 months for the entire cohort (range, o1 month to 146 months) and 5.5 years for censored patients. At diagnosis, the median AMC was 630/ml (range 30-4040, interquartile range 470-833) and the median ALC was 1230/ml (range 140-9200, interquartile range 870-1770). All patients were treated initially with CHOP or R-CHOP. The estimated 5-year OS for the entire cohort was 64%.
Elevation in the AMC and relative lymphopenia are adverse prognostic factors
To determine the prognostic significance of the AMC and ALC, both values were obtained from a CBC at the time of initial diagnosis. On univariate analysis, the AMC predicted OS as a continuous variable, whereas the relationship between the ALC and OS approached, but did not reach, statistical significance (Table 2 ). An elevated AMC, analyzed as a dichotomized variable using a median split, was associated with inferior OS on univariate analysis (hazard ratio 2.77, 95% confidence interval 1.92-4.09, Po0.0001). Lymphopenia defined as an ALC p1000/ml, was associated with inferior OS (hazard ratio 1.74, 95% confidence interval 1.23-2.43, P ¼ 0.002). For comparison, each of the five factors that comprise the IPI was included in the analysis. Of these, performance status (X2), lactate dehydrogenase (4normal), number of extranodal sites (41) and Ann Arbor stage (stage III/IV) were of prognostic significance on univariate analysis (Table 2) . As components of the IPI are important and commonly used prognostic factors in DLBCL, we included components of the IPI in a multivariate analysis with both the AMC and ALC as dichotomized variables. As summarized in Table 2 , only the AMC, ALC and lactate dehydrogenase were independently significant prognostic factors for OS, with hazard ratios of 2.65 (95% confidence interval 1.82-3.92, Po0.0001), 1.56 (95% confidence interval 1.10-2.22, P ¼ 0.01) and 1.61 (95% confidence interval 1.12-2.33, P ¼ 0.01), respectively. Both the AMC and ALC remained independent predictors of survival when adjusted for the IPI alone (high risk vs low/intermediate risk) on multivariate analysis, with hazard ratios of 2.61 (95% confidence interval 1.83-3.80, Po0.0001) and 1.76 (95% confidence interval 1.25-2.47, P ¼ 0.001), respectively. Similarly, the AMC and ALC were independently significant predictors of PFS when adjusted for components of the IPI on multivariate analysis, with hazard ratios of 2.5 (95% confidence interval 1.6-4.0, Po0.0001) and 3.2 (95% confidence interval 2.0-5.1, Po0.0001), respectively.
An AMC X630/ml was associated with 4.8 years median OS (94 events observed; 95% confidence interval 3.7-6.8 years) and an estimated 5-year OS of 49% (95% confidence interval 42-57%). In contrast, median OS has not been reached (43 events observed; 95% confidence interval 8.3-12.2 years) for patients with an AMC o630/ml, with an estimated 5-year OS of 80% (95% confidence interval 74-86%; Figure 1a) . Similarly, an elevated AMC was associated with inferior PFS (89 vs 46 events observed; median PFS 5.0 years vs not reached; 5-year PFS 50 vs 74%, Po0.0001), as shown in Figure 1b . Lymphopenia (ALC p1000/ml) was associated with inferior survival, with a median OS of 6.3 years (59 events observed; 95% confidence interval 2.9-11.6 years) and PFS of 2.4 years (66 events observed; 95% confidence interval 1.3-11.6 years) with estimated 5-year OS and PFS of 53% (95% confidence interval 44-62%) and 44% (95% confidence interval 35-54%), respectively. In contrast, the median OS (78 events observed) and PFS (69 events observed) had not been reached, with estimated 5-year OS and PFS of 70% (95% confidence interval 64-76%) and 71% (95% confidence interval 66-78%), respectively, for patients with an ALC 41000/ ml (Figures 1c and d) .
The AMC/ALC prognostic score identifies poor-risk patients and provides additional prognostic information when superimposed on the IPI Like the IPI, use of the AMC or ALC as single variables was unable to identify a subset of truly high-risk patients, even though each variable alone was able to identify poor-risk patients with 5-year OS comparable to poor-risk patients identified by the IPI. Furthermore, factors included in the IPI may be co-dependent variables. For example, patients in this cohort with advanced stage disease were more likely to have an elevated lactate dehydrogenase (Po0.0001). In contrast, the AMC and ALC are each independent from the other (data not shown). Therefore, we combined the dichotomized AMC and ALC to generate the AMC/ALC prognostic score and stratified patients into three risk groups: low-(AMC o630/ml and ALC 41000/ml), intermediate-(AMC X630/ml or ALC p1000/ml) and high-risk (AMC X630/ml and ALC p1000/ml) populations.
PFS and OS were analyzed using either the AMC/ALC prognostic score or the IPI. The estimated 5-year PFS among low-and intermediate-risk patients stratified by the AMC/ALC prognostic score was 83 and 59%, respectively (Figure 2a) . Similarly, the estimated 5-year PFS among low-, low-intermediate-and high-intermediate-risk patients was 80, 53 and 46%, respectively, using the IPI (Figure 2b) . The AMC/ALC prognostic score identified a group of poor-risk patients with a median PFS of 14 months (95% confidence interval 10-23 months) and an estimated 5-year PFS of 30%. Similarly, the median PFS was 14 months (95% confidence interval 7-95 months) and the estimated 5-year PFS was 37% among high-risk patients identified using the IPI. For both low-and intermediate-risk patients, identified by either the AMC/ALC prognostic score or the IPI, median OS either had not been reached or exceeded 6 years (in low-intermediate-risk IPI). In contrast, the median OS was 2.2 years (95% confidence interval 1.7-3.8 years), with an estimated 5-year OS of 32%, among high-risk patients identified using the AMC/ALC prognostic score (Figure 2c) . By comparison, a median OS of 2.1 years (95% confidence interval 1.2-7.9 years) was observed in high-risk patients identified by the IPI, with a 38% 5-year OS (Figure 2d) . Clearly, the AMC/ALC prognostic score was able to risk-stratify patients in a manner comparable to the IPI.
We next examined the AMC/ALC prognostic score's performance in the rituximab era by confining our analysis to only those patients treated with R-CHOP (n ¼ 256). As shown in Figure 3 , the AMC/ALC prognostic score was able to identify low-, intermediate-and high-risk patients with 5-year PFS ranging from 26 to 88% and 5-year OS ranging from 28 to 88% (Figures 3a and c) . In contrast, high-risk patients identified by the IPI experienced a 44% 5-year PFS and OS (Figures 3b and d) . The AMC/ALC prognostic score not only remained prognostically significant in the rituximab era, but was at least as proficient as the IPI in identifying high-risk patients. The AMC/ALC score remains an independently significant prognostic factor when adjusting for the IPI. Therefore, we sought to determine whether it may provide additional prognostic information when combined with the IPI. To test this possibility, both low- (Figure 4a ) and intermediate-risk (Figure 4b ) patients were segregated by the IPI. There were too few high-risk patients to make a similar analysis in this subgroup meaningful. The 158 low-risk and 169 intermediate-risk (highintermediate and low-intermediate were combined) patients identified by the IPI were subsequently risk stratified using the AMC/ALC prognostic score. In both cases, the AMC/ALC score was able to further risk-stratify these patients, although this was most significant in patients identified as intermediate risk by the IPI (Figure 4b ). Among these patients, 5-year OS ranged from 64 to 77% among low-and intermediate-risk patients identified by the AMC/ALC prognostic score. In contrast, 21% of patients identified by the IPI as 'intermediate-risk', upon further riskstratification by the AMC/ALC prognostic score, were found to have dismal outcomes, with a median OS of only 19 months (95% confidence interval 12-32 months) and 5-year OS of 21% (Figure 4b ). Similar results were obtained when intermediaterisk patients treated with R-CHOP were risk-stratified by the AMC/ALC prognostic score ( Figure 5 ). In this case, the high-risk subgroup experienced a median OS of 17 months (95% confidence interval 11-26 months) and 5-year OS of 17%.
The AMC/ALC prognostic score, derived from values easily obtained from a CBC, is comparable to the IPI in its ability to risk stratify patients in the pre-and post-rituximab era. Furthermore, it provides additional prognostic information when used to sub-stratify risk groups obtained from the IPI, leading to the identification of high-risk patients otherwise classified as intermediate risk by the IPI alone. 
Discussion
Recent work, based on large gene-expression profiling and immunohistochemistry-based studies in a variety of histological subtypes of NHL, shows that the quality of tumor-infiltrating lymphocytes and myeloid-derived cells provide valuable prognostic information that, in some cases, may exceed that provided by consideration of the tumor characteristics alone. 3, 19, 34 This implies that a prognostic system that considers features of the tumor-bearing host and the tumor microenvironment may provide prognostic information that is independent from conventional prognostic models. Therefore, we sought to investigate whether the AMC and ALC, as biomarkers for host immunity and the tumor microenvironment, affect survival in DLBCL.
Myeloid-lineage cells, including monocytes and their progeny, promote tumorigenesis. [35] [36] [37] [38] These myeloid-derived cells contribute to the suppression of host antitumor immunity and have an important role in tumor angiogenesis. Not surprisingly then, development of peripheral blood neutrophilia or monocytosis are adverse prognostic factors in multiple solid tumors. [39] [40] [41] [42] [43] [44] [45] [46] Multiple mechanisms, none of which are mutually exclusive, may be invoked to explain the prognostic significance of a relative monocytosis in DLBCL. First, monocytes and monocytic myeloid-derived suppressor cells suppress host antitumor immunity by a variety of different mechanisms. 47, 48 For example, we have previously shown that both peripheral blood monocytes and their progeny within the tumor microenvironment inducibly express the T-cell co-inhibitory ligand B7-H1 (PD-L1).
47 B7-H1 expression was found to directly impair the expansion and effector functions of tumor-specific T cells, and when expressed by myeloid-lineage cells within the tumor microenvironment led to the expansion of suppressive regulatory T cells. Next, a considerable body of evidence highlights the role of myeloid-lineage cells in supporting tumor angiogenesis, including a subpopulation of monocytes expressing the angiopoietin-2 receptor Tie2. 49, 50 Given the role of macrophages in lymphomagenesis, peripheral blood monocytes may represent an important reservoir of macrophage precursors. To address this possibility, the density of CD68 þ lymphomaassociated macrophages in lymph nodes was examined in this study (data not shown). Although a direct correlation between the AMC and the density of LAMs may have been anticipated, no such correlation was observed. This suggests that the heterogeneity of LAM density observed may be explained by differences in monocyte recruitment and the retention of tissueresident macrophages, as opposed to the AMC. Finally, monocytes are an important source of soluble mediators, like B-lymphocyte stimulator, that support the growth and survival of both normal and malignant B cells. [51] [52] [53] Not surprisingly then, monocytes have been convincingly shown to support the growth of malignant lymphocytes in both T-and B-cell NHL. 26, 54 The vast majority of DLBCL originate from either germinalcenter B cells (that is, GCB type) or from B cells with a geneexpression profile resembling activated B cells (that is, ABC type). Each DLBCL subtype may preferentially exploit a particular pathway during lymphomagenesis. For example, both the STAT3 and nuclear factor-kB pathways have been implicated in the pathogenesis of ABC-DLBCL and chemokine and cytokine genes targeted by STAT3 and nuclear factor-kB regulate monocyte recruitment and ultimately LAM function and polarity. Similarly, inflammatory and hematopoietic cytokines that contribute to monocyte expansion (and the 'leukemoid reaction') may be differentially expressed in DLBCL, raising the possibility that differences in the AMC may, at least in part, be explained by differences in the cell of origin (either GCB or non-GCB). To examine this possibility, DLBCL specimens, in which immunohistochemical staining for CD10, BCL-6 and MUM-1 was performed at diagnosis (n ¼ 42), were classified as either GCB or non-GCB in origin using the Hans algorithm (data not shown).
14 No significant difference in the mean AMC was observed between GCB and non-GCB DLBCL and the AMC remained an independent prognostic factor when adjusting for the cell of origin on multivariate analysis (data not shown). Although this observation, limited by the small sample size, suggests that the cell of origin in DLBCL may not be an important determinant of monocyte expansion in DLBCL, it certainly does not exclude the real possibility that genes differentially expressed in GCB-or non-GCB-type DLBCL regulate the biology of monocytes and their progeny within the tumor microenvironment.
The contribution of immune suppression in lymphomagenesis, illustrated by post-transplant lymphoproliferative disease and HIV-associated lymphomas, highlights the important contribution of T and NK cells in immune surveillance. Therefore, lymphopenia is considered a surrogate marker of host immunological incompetence. 24, 55 In addition, lymphocytes (including natural killer cells) are important mediators of antibody-dependent cell-mediated cytotoxicity, and may be required for rituximab-mediated, antibody-dependent cellmediated cytotoxicity-dependent destruction of malignant B cells. 56 Not surprisingly then, lymphopenia is an adverse prognostic factor in indolent and aggressive NHL, including DLBCL. For example, lymphopenia is a poor-risk feature in DLBCL patients treated with either CHOP or R-CHOP and in GCB-and non-GCB-type DLBCL. 23, 31 More recently, the development of new-onset lymphopenia following autologousperipheral blood stem cell transplantation was associated with a significant increase in the risk of disease relapse. 32 Patients with an ALC o1000/ml following autologous-peripheral blood stem cell transplantation had an incidence of disease relapse of 92%, compared with a relapse rate of 19% among patients without lymphopenia.
The evidence linking both myeloid-lineage cells and lymphopenia with lymphomagenesis, and in this study with poor PFS and OS, raises the possibility that strategies which deplete tumorigenic myeloid-lineage cells or reverse lymphopenia may represent novel therapeutic strategies in DLBCL. Therapeutic strategies targeting myeloid-lineage cells, including myeloidderived suppressor cells, are currently being investigated in solid tumors and may warrant further investigation in NHL. 57 In contrast, manipulation of the lymphocyte content administered with autologous stem cells during autologous-peripheral blood stem cell transplantation, in hopes of raising the ALC and improving survival, is the subject of an ongoing phase III clinical trial in relapsed NHL (NCT00566228).
Given the need for improved prognostic models in DLBCL, other predictors have been investigated. Some of these, initially identified before the introduction of rituximab, no longer provide useful prognostic information in the rituximab era. 8, 9 Other predictive models based on gene-expression profiling, while prognostically useful, are cumbersome, difficult to interpret, require the availability of suitable biopsy material and are cost prohibitive. 3, 5 Although the introduction of interim positron emission tomography analysis and risk-adapted therapy is being explored, this will require further validation, as the interpretation of interim positron emission tomography scans is not always reproducible and the rate of false-positive interim scans is not insignificant. 17, 18 Despite the growing body of evidence highlighting the relationship between the tumor microenvironment and lymphomagenesis, the incorporation of prognostic variables associated with the tumor microenvironment into routine clinical practice has remained a challenge, as most studies exploring this relationship are based on geneexpression profiling or immunohistochemistry data. In contrast, the AMC/ALC prognostic score, derived from a CBC at diagnosis, is widely available and may be easily incorporated into clinical practice. Furthermore, the AMC/ALC prognostic score provided prognostic information independently of that included in the IPI and was able to provide additional prognostic information when used in conjunction with the IPI. This was particularly true for low-intermediate-and high-intermediaterisk patients, which collectively accounted for nearly 50% of the patients in our series. When patients identified as intermediate risk by the IPI were further risk stratified by the AMC/ALC prognostic score, approximately 20% of these patients were identified as high risk, as evidenced by the fewer than 20% longterm survivors, even in the rituximab era.
Given the limited number of patients included in this retrospective study, the AMC/ALC prognostic score will require validation in an independent cohort of patients. Despite the need for independent validation, the AMC/ALC prognostic score demonstrates that variables related to the host immune response and the tumor microenvironment are worth consideration when generating prognostic indices in NHL, as these variables may provide additional prognostic information independently from conventional patient-and tumor-specific factors.
